VXAA-1.1 is under clinical development by Vaxart and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect VXAA-1.1’s likelihood of approval (LoA) and phase transition for Influenza A Virus, H1N1 Subtype Infections took place on 10 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 10 Oct 2022 increased VXAA-1.1’s LoA and PTSR for Seasonal Influenza.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VXAA-1.1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
VXAA-1.1 is under development for the prevention of seasonal influenza adenovector based H1N1 strain A infections. The vaccine candidate is administered through oral route as a coated tablet. It is a monovalent recombinant vaccine consists of a non-replicating adenovirus vector type 5 (Ad5) upon which an adjuvant (TLR3 ligand) is coupled to a target antigen hemagglutinin (HA) from avian influenza.
Vaxart, formerly Aviragen Therapeutics, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer, and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.
Quick View VXAA-1.1 LOA Data
|Highest Development Stage|